← Back to Clinical Trials
Recruiting NCT01670695

NCT01670695 A Prospective Cohort Study of IgG4RD in China

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01670695
Status Recruiting
Phase
Sponsor Peking Union Medical College Hospital
Condition IgG4-related Disease
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2012-01
Primary Completion 2032-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2012-01 with a primary completion date of 2032-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.

Eligibility Criteria

Inclusion Criteria: * Males and females * Age 18-75 years old with informed consent * Patients with IgG4-RD: 1. swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions; 2. elevated serum IgG4 (\>1.35 g/L) 3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed); 4. exclusion of other diseases. Exclusion Criteria: * Females planning to bear a child recently or with childbearing potential * Concurrent severe and/or uncontrolled and/or unstable diseases * Patient with malignancy

Contact & Investigator

Central Contact

Hua Chen, MD

✉ chen77hua@gmail.com

📞 86-10-69158797

Principal Investigator

Wen Zhang, MD

PRINCIPAL INVESTIGATOR

Deptment of Rheumatology, Peking Union Medical College Hospital

Frequently Asked Questions

Who can join the NCT01670695 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying IgG4-related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01670695 currently recruiting?

Yes, NCT01670695 is actively recruiting participants. Contact the research team at chen77hua@gmail.com for enrollment information.

Where is the NCT01670695 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT01670695 clinical trial?

NCT01670695 is sponsored by Peking Union Medical College Hospital. The principal investigator is Wen Zhang, MD at Deptment of Rheumatology, Peking Union Medical College Hospital. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology